Hypermarcas plan is to grow 2% to 3% above the average for the market until 2021

The President Hypermarcas, Claudio Bergamo, began meeting with analysts and investors of the company stating that the current management of the company's objective is to seek growth. According to him, the mandate of executives with shareholders is not treating the company as a "cash cow" (expression that indicates mature companies and without so much room to grow).
The strategic plan of the company for up to 2021, said Bergamo, considers the prospect of growth at rates 2% to 3% higher than the average of the pharmaceutical market.
Bergamo stated that the company is focused on financing this growth with your own cash generation and keeping a net debt close to zero. The dividend distribution policy must also be maintained, he said.
Growth opportunities
The President listed some Hypermarcas segments in which the company sees growth opportunities today.
According to him, the company can grow in markets where the company already is relevant. According to the Executive, there is still room for new releases of brand extensions.
Another strategy of the company, according to Bergamo, is to increase the participation in markets where the company today has low presence and act in less developed markets so far in Brazil.
On the development of new markets, the Executive said that not necessarily this process demand high investments in the discovery of new molecules. According to him, the market has room for innovations in the form of application of medicines.